Tovecimig Combination Demonstrates Response and Progression Gains in Advanced Biliary Tract Cancer

Patients with advanced biliary tract cancer who have exhausted their initial treatments now have clinical evidence supporting a combination therapy that halts disease progression significantly longer than standard chemotherapy. Results from a late-stage trial show that pairing an experimental bispecific antibody with a conventional chemotherapy agent more than triples the likelihood of tumor shrinkage.[1][2]

The data, presented at the European Society for Medical Oncology congress in Madrid and published simultaneously in the Journal of Clinical Oncology, offers a rare positive signal in a notoriously difficult-to-treat malignancy. Biliary tract cancers are aggressive, and once patients progress past first-line treatments like gemcitabine and cisplatin, effective options practically vanish.[1][3]

The phase 2/3 COMPANION-002 trial evaluated tovecimig—an investigational drug developed by Compass Therapeutics—in combination with paclitaxel against paclitaxel alone. The study enrolled 168 patients with advanced, metastatic, or recurrent disease who had already received one prior systemic therapy.[2][3]

Tovecimig operates as a first-in-class bispecific antibody designed to choke off a tumor's blood supply. It simultaneously targets two distinct angiogenic pathways: vascular endothelial growth factor A and Delta-like ligand 4. By blocking both, the drug aims to prevent the cancer from building the new blood vessels it needs to grow and spread.[1][4]

Tripling the Response Rate

The trial met its primary endpoint decisively, with the combination of tovecimig and paclitaxel eliciting an objective response rate of 18.0%, compared to just 5.3% for patients receiving paclitaxel alone. This means nearly one in five patients saw their tumors measurably shrink, a notable achievement in a second-line setting where historical response rates hover at or below 5%.[1][2][3]

The responses were also durable, lasting a median of 4.9 months for those on the experimental combination. Furthermore, the overall disease control rate—which includes patients whose cancer stabilized rather than shrank—reached 62.2% in the combination arm, significantly outpacing the 36.8% seen in the control group.[2][3]

The treatment also succeeded in its key secondary endpoint of progression-free survival. Patients receiving the doublet therapy lived a median of 4.7 months before their disease advanced, compared to 2.6 months for those on paclitaxel alone. This translates to a 56% reduction in the risk of disease progression or death.[1][2][4]

Researchers paid specific attention to a prespecified subgroup of patients with intrahepatic cholangiocarcinoma, a cancer originating in the bile ducts inside the liver. This group comprised 92 of the 168 trial participants and demonstrated consistent benefits, showing a 15.3% response rate against zero for the control arm, and a median progression-free survival of 5.1 months versus 3.0 months.[3][4]

The Survival Data Confound

Despite the clear advantages in halting tumor growth, the trial did not demonstrate a statistically significant improvement in overall survival during its primary intention-to-treat analysis. Patients in the combination arm lived a median of 8.9 months, compared to 9.4 months for those receiving only paclitaxel.[1][2]

Lead investigator Dr. Nilofer S. Azad of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center noted that this survival data was heavily confounded by the trial's compassionate crossover design. Patients randomly assigned to the paclitaxel-alone arm were permitted to switch to the tovecimig combination once independent reviewers confirmed their cancer had progressed.[1][3]

"Altogether, this combination presents a promising new strategy for patients with biliary tract cancer," Azad said during her presentation. Ultimately, 31 of the 57 patients in the control arm crossed over, meaning 85% of all patients in the study eventually received tovecimig, blurring the survival distinctions between the two original cohorts.[1][2][3]

Exploratory analyses highlighted the impact of this crossover on the final survival figures. Patients who switched to tovecimig after progressing on paclitaxel achieved a median overall survival of 12.8 months. In contrast, control-arm patients who did not cross over lived a median of just 6.1 months.[3]

To estimate what the survival difference might have been without the crossover, researchers conducted a post-hoc analysis using a recognized statistical adjustment method. That calculation yielded an overall survival hazard ratio of 0.85, suggesting a 15% reduction in the risk of death, though the finding remains exploratory rather than definitive.[3][4]

Toxicity and Regulatory Hurdles

The increased efficacy of the dual-pathway blockade came with a higher burden of side effects for the patients receiving it. Grade 3 or higher treatment-emergent adverse events occurred in 93.5% of patients receiving the combination, compared to 64.2% of those on paclitaxel alone.[2][4]

The most common severe adverse events included fatigue, neutropenia, and hypertension, which is a known side effect of anti-angiogenic drugs. Treatment-emergent adverse events leading to death were reported in 5.6% of the combination group and 1.9% of the control group, underscoring the aggressive nature of both the disease and the treatment.[2][4]

The lack of a clean overall survival benefit complicates the drug's regulatory path moving forward. Compass Therapeutics has indicated it plans to meet with the U.S. Food and Drug Administration to discuss a potential Biologics License Application, though regulators traditionally favor clean survival data in oncology approvals.[3]

The company has maintained that the statistically significant improvements in both response rate and progression-free survival demonstrate clinically meaningful activity. They argue these metrics, combined with the subset analyses adjusting for crossover, warrant approval in a population with severe unmet needs.[3]

Independent experts reviewing the data acknowledged the drug's activity but pointed to the need for further validation before standard practice changes. Dr. Sebastián Mondaca of the Pontificia Universidad Católica de Chile noted that the results are encouraging given the low bar in second-line treatment.[1]

However, Mondaca cautioned that a phase III trial comparing the combination against a standard regimen like FOLFOX would ideally be needed to prove a clear survival benefit. "On the other hand, tovecimig has shown clinical activity, and given the high unmet need of these patients a formal review by guideline committee is warranted," he added.[1]

For now, the COMPANION-002 results establish tovecimig as a highly active agent capable of disrupting tumor angiogenesis in biliary tract cancer. Whether the progression delays are sufficient to secure regulatory approval will depend on upcoming discussions and potential subsequent trials.[1][3]